Season 2-Episode 49-Shingrix® vs. Zostavax®: A Shingles Vaccine Analysis Continued


Dr. Michael Hogue, PharmD, FAPhA, FNAP, associate dean of the center of faith and hope and professor of pharmacy at Samford University’s McWhorter School of Pharmacy who is also a vaccine expert, returns to Healthy Dose® to talk more about the new Shingrix® vaccine and comparing it to the vaccine that we already have available Zostavax®.

Last week, on Healthy Dose® Episode 48, we discussed who should get the shingles vaccine and what the Centers for Disease Control and Prevention (CDC) recommends patients to do now that the new shingles vaccine is approved and recommended above Zostavax®.

On today’s episode, Dr. Hogue will discuss more about new the vaccine for shingles, Shingrix®, in terms of side effects, costs, and the effectiveness of the vaccine compared to Zostavax® based on the most current research available along with what other vaccines can be given at the same time and when the new vaccine could come to market.

Listen now below to Tuesday’s new Healthy Dose® episode which aired on 12-5-17 at 5pm on WVSU FM91.1 Birmingham! #healthydose #samfordpharmacy #WVSU #shingles #zostervaccines #shingrix #zostavaxhogue-michael


The new shingles vaccine, Shingrix®, has a 95% effectiveness rate in preventing the shingles virus that will last for 20 years as opposed to Zostavax® which is about 50% effective and lasts about 6 years.

Shingrix package insert

Zostavax package insert

CDC Recommendations

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s